miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer cells to 5-FU by up-regulation of Cdc2 activities in 786-O

Chen, Binghai; Duan, Lujing; Yin, Guangming; Tan, Jianxin; Jiang, Xianzhen

doi:10.1179/1973947813y.0000000092

Cited by 44 publications

(38 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In line with our findings, Huang et al (2017) reported that miR-381 could enhance DDP sensitivity of non-small cell lung cancer cells through nuclear factor-ĸB signaling inhibition. Moreover, several other studies have reported that lowed miR-381 expression was implicated with chemoresistance of other drugs in cancers (Chen et al, 2013;Xu Figure 5 miR-381 promoted DDP sensitivity of breast cancer cells by directly suppressing MDR1 expression. MCF-7/DDP and MDA-MB-231/ DDP cells were transfected with miR-con, miR-381, miR-381þVector, or miR-381þMDR1; and MCF-7 and MDA-MB-231 cells were transfected with anti-miR-con, anti-miR-381, anti-miR-381þsi-con, or anti-miR-381þsi-MDR1, followed by determination of MDR1 expression by qRT-PCR analysis (A and B), IC50 of DDP by MTT assay (C and D), and cell apoptotic rate by flow cytometry analysis (E and F).…”

Section: Discussionmentioning

confidence: 97%

miR‐381 overcomes cisplatin resistance in breast cancer by targeting MDR1

Wang

et al. 2018

Cell Biology International

View full text Add to dashboard Cite

Increasing evidence suggests the involvement of microRNA-381 (miR-381) in chemoresistance of cancer treatment. However, its function and molecular mechanisms in breast cancer chemoresistance are still not well elucidated. In the present study, we aimed to investigate the functional role of miR-381 in cisplatin (DDP) resistance of breast cancer and discover the underlying molecular mechanism. The expression levels of miR-381 and MDR1 were detected by quantitative real-time PCR (qRT-PCR) and Western blot analysis in breast cancer tissues and cell lines. The DDP sensitivity and cell apoptosis of breast cancer cells were determined by MTT assay and flow cytometric analysis, respectively. The relationship between miR-381 and MDR1 was explored by target prediction and luciferase reporter analysis. miR-381 was decreased in DDP-resistant breast cancer tissues and cell lines. Low miR-381 expression was correlated with poor prognosis of breast cancer patients. miR-381 overexpression improved DDP sensitivity of MCF-7/DDP and MDA-MB-231/DDP cells. Conversely, miR-381 inhibition lowered the response of MCF-7 and MDA-MB-231 to DPP. Moreover, miR-381 could directly suppress multidrug resistance 1 (MDR1) expression. MDR1 knockdown could overcome DDP resistance in MCF-7/DDP and MDA-MB-231/DDP cells, while MDR1 overexpression led to DDP resistance in MCF-7 and MDA-MB-231 cells. Notably, MDR1 overexpression counteracted the inductive effect of miR-381 mimics on DDP sensitivity of MCF-7/DDP and MDA-MB-231/DDP cells. On the contrary, miR-381 inhibition-mediated DDP resistance in MCF-7 and MDA-MB-231 cells was reversed by MDR1 knockdown. In summary, miR-381 could overcome DDP resistance of breast cancer by directly targeting MDR1, providing a novel therapeutic target for breast cancer chemoresistance.

show abstract

Section: Discussionmentioning

confidence: 97%

miR‐381 overcomes cisplatin resistance in breast cancer by targeting MDR1

Wang

et al. 2018

Cell Biology International

View full text Add to dashboard Cite

show abstract

“…For tumor growth, miR-381 could inhibit cell proliferation in colon cancer through targeting LRH-1 (17), in glioma through targeting BRD7 (17) and in renal cancer through targeting WEE1 (18). MiR-381 also could sensitize glioblastoma cells to temozolomide by targeting neurofilament light polypeptide (19).…”

Section: Discussionmentioning

confidence: 99%

MiR-381 inhibits migration and invasion in human gastric carcinoma through downregulatedting SOX4

Zhang¹,

Huang²,

Long³

2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. Aberrant expression of microRNAs (miRs) serves essential roles in the generation and progression of various types of human cancer. In the present study, the expression and biological functions of miR-381 in human gastric carcinoma (GC) were focused upon. The results of reverse transcription-quantitative polymerase chain reaction analysis revealed that the expression of miR-381 was significantly downregulated in GC tissue samples. Furthermore, low expression of miR-381 was identified to be associated with lymphatic metastasis and advanced tumor-node-metastasis stage (III+IV). Upregulation of miR-381 inhibited the migration and invasion of GC SGC-7901 cells through SRY-Box 4 (SOX4)-mediated epithelial-mesenchymal transition. Finally, long non-coding (lnc) RNA-taurine upregulatedted 1 (non-protein coding) (TUG1) was confirmed as a negatively regulator of miR-381 expression in SGC-7901 cells. Taken together, the results of the current study indicate that the downregulation of miR-381 by lncRNA-TUG1 promoted the metastasis of GC cells by inhibiting SOX4. Thus, targeting miR-381 may be a novel therapeutic option for the treatment of patients with GC.

show abstract

“…For instance, increased serum levels of miR-183 correlate with patients' resistance to NK cytotoxicity [278] while miR-942 confers resistance of RCC patients to sunitinib [279]. It was also shown that miR-381 enhances the sensitivity of RCC cells to 5-fluorouracil [280].…”

Section: Renal Cancermentioning

confidence: 99%

TGF-β and microRNA Interplay in Genitourinary Cancers

Bogusławska¹,

Kryst

Poletajew

et al. 2019

Cells

View full text Add to dashboard Cite

Genitourinary cancers (GCs) include a large group of different types of tumors localizing to the kidney, bladder, prostate, testis, and penis. Despite highly divergent molecular patterns, most GCs share commonly disturbed signaling pathways that involve the activity of TGF-β (transforming growth factor beta). TGF-β is a pleiotropic cytokine that regulates key cancer-related molecular and cellular processes, including proliferation, migration, invasion, apoptosis, and chemoresistance. The understanding of the mechanisms of TGF-β actions in cancer is hindered by the “TGF-β paradox” in which early stages of cancerogenic process are suppressed by TGF-β while advanced stages are stimulated by its activity. A growing body of evidence suggests that these paradoxical TGF-β actions could result from the interplay with microRNAs: Short, non-coding RNAs that regulate gene expression by binding to target transcripts and inducing mRNA degradation or inhibition of translation. Here, we discuss the current knowledge of TGF-β signaling in GCs. Importantly, TGF-β signaling and microRNA-mediated regulation of gene expression often act in complicated feedback circuits that involve other crucial regulators of cancer progression (e.g., androgen receptor). Furthermore, recently published in vitro and in vivo studies clearly indicate that the interplay between microRNAs and the TGF-β signaling pathway offers new potential treatment options for GC patients.

show abstract

miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer cells to 5-FU by up-regulation of Cdc2 activities in 786-O

Abstract: miR-381 increases sensitivity of 786-O cells to 5-FU by inhibitory WEE1 and increase of Cdc2 activity.

Cited by 44 publications

References 34 publications

miR‐381 overcomes cisplatin resistance in breast cancer by targeting MDR1

miR‐381 overcomes cisplatin resistance in breast cancer by targeting MDR1

MiR-381 inhibits migration and invasion in human gastric carcinoma through downregulatedting SOX4

TGF-β and microRNA Interplay in Genitourinary Cancers

Contact Info

Product

Resources

About